Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs

Denis J Marcellin-Little, Mark G. Papich, Daniel C. Richardson, David J. DeYoung

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives - To compare cefazohn pharmacokinetics in serum and concentrations in tissues during total hip arthroplasty in dogs with and without hip dysplasia, and to calculate the optimal dosage of cefazolin for prophylactic use during total hip arthroplasty. Animals - 10 dogs with hip dysplasia and 3 clinically normal dogs. Procedure - Blood samples and tissue specimens from the coxofemoral joint capsule, acetabulum, and femur were obtained during unilateral total hip arthroplasty. Cefazolin concentrations in serum and tissue specimen supernatant were determined, using high-performance liquid chromatography, for use in pharmacokinetic analysis. Mathematical simulation of serum cefazolin concentrations was used to to predict the optimal dose. Results - Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for α. 4.74 min for t1/2α, 0.015 (0.004) min-1 for β, and 46.83 mm for t1/2β. Significant difference was not detected for cefazolin distribution and elimination between dogs with and without hip dysplasia. Additionally, significant difference was not observed in pharmacokinetic parameters describing distribution and elimination between the first and second doses of cefazolin The predicted optimal dosage regimen was 8 mg/ kg of body weight, IV, every hour or 22 mg/kg, IV, every 2 hours. Clinical Relevance - For prophylactic IV treatment during total hip arthroplasty, use of cefazolin at a dosage of 8 mg/kg every hour or 22 mg/kg every 2 hours should maintain serum cefazolin concentrations at least 10X the minimum inhibitory concentration for 3 to 4 hours.

Original languageEnglish (US)
Pages (from-to)720-723
Number of pages4
JournalAmerican Journal of Veterinary Research
Volume57
Issue number5
StatePublished - May 1 1996
Externally publishedYes

Fingerprint

cefazolin
Cefazolin
hips
Arthroplasty
pharmacokinetics
Hip
Pharmacokinetics
Dogs
blood serum
dogs
hip dysplasia
Hip Dislocation
dosage
Serum
Joint Capsule
Acetabulum
Microbial Sensitivity Tests
minimum inhibitory concentration
femur
Femur

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. / Marcellin-Little, Denis J; Papich, Mark G.; Richardson, Daniel C.; DeYoung, David J.

In: American Journal of Veterinary Research, Vol. 57, No. 5, 01.05.1996, p. 720-723.

Research output: Contribution to journalArticle

Marcellin-Little, Denis J ; Papich, Mark G. ; Richardson, Daniel C. ; DeYoung, David J. / Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. In: American Journal of Veterinary Research. 1996 ; Vol. 57, No. 5. pp. 720-723.
@article{f754b6cc58454393a85ace6e365613ce,
title = "Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs",
abstract = "Objectives - To compare cefazohn pharmacokinetics in serum and concentrations in tissues during total hip arthroplasty in dogs with and without hip dysplasia, and to calculate the optimal dosage of cefazolin for prophylactic use during total hip arthroplasty. Animals - 10 dogs with hip dysplasia and 3 clinically normal dogs. Procedure - Blood samples and tissue specimens from the coxofemoral joint capsule, acetabulum, and femur were obtained during unilateral total hip arthroplasty. Cefazolin concentrations in serum and tissue specimen supernatant were determined, using high-performance liquid chromatography, for use in pharmacokinetic analysis. Mathematical simulation of serum cefazolin concentrations was used to to predict the optimal dose. Results - Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for α. 4.74 min for t1/2α, 0.015 (0.004) min-1 for β, and 46.83 mm for t1/2β. Significant difference was not detected for cefazolin distribution and elimination between dogs with and without hip dysplasia. Additionally, significant difference was not observed in pharmacokinetic parameters describing distribution and elimination between the first and second doses of cefazolin The predicted optimal dosage regimen was 8 mg/ kg of body weight, IV, every hour or 22 mg/kg, IV, every 2 hours. Clinical Relevance - For prophylactic IV treatment during total hip arthroplasty, use of cefazolin at a dosage of 8 mg/kg every hour or 22 mg/kg every 2 hours should maintain serum cefazolin concentrations at least 10X the minimum inhibitory concentration for 3 to 4 hours.",
author = "Marcellin-Little, {Denis J} and Papich, {Mark G.} and Richardson, {Daniel C.} and DeYoung, {David J.}",
year = "1996",
month = "5",
day = "1",
language = "English (US)",
volume = "57",
pages = "720--723",
journal = "American Journal of Veterinary Research",
issn = "0002-9645",
publisher = "American Veterinary Medical Association",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs

AU - Marcellin-Little, Denis J

AU - Papich, Mark G.

AU - Richardson, Daniel C.

AU - DeYoung, David J.

PY - 1996/5/1

Y1 - 1996/5/1

N2 - Objectives - To compare cefazohn pharmacokinetics in serum and concentrations in tissues during total hip arthroplasty in dogs with and without hip dysplasia, and to calculate the optimal dosage of cefazolin for prophylactic use during total hip arthroplasty. Animals - 10 dogs with hip dysplasia and 3 clinically normal dogs. Procedure - Blood samples and tissue specimens from the coxofemoral joint capsule, acetabulum, and femur were obtained during unilateral total hip arthroplasty. Cefazolin concentrations in serum and tissue specimen supernatant were determined, using high-performance liquid chromatography, for use in pharmacokinetic analysis. Mathematical simulation of serum cefazolin concentrations was used to to predict the optimal dose. Results - Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for α. 4.74 min for t1/2α, 0.015 (0.004) min-1 for β, and 46.83 mm for t1/2β. Significant difference was not detected for cefazolin distribution and elimination between dogs with and without hip dysplasia. Additionally, significant difference was not observed in pharmacokinetic parameters describing distribution and elimination between the first and second doses of cefazolin The predicted optimal dosage regimen was 8 mg/ kg of body weight, IV, every hour or 22 mg/kg, IV, every 2 hours. Clinical Relevance - For prophylactic IV treatment during total hip arthroplasty, use of cefazolin at a dosage of 8 mg/kg every hour or 22 mg/kg every 2 hours should maintain serum cefazolin concentrations at least 10X the minimum inhibitory concentration for 3 to 4 hours.

AB - Objectives - To compare cefazohn pharmacokinetics in serum and concentrations in tissues during total hip arthroplasty in dogs with and without hip dysplasia, and to calculate the optimal dosage of cefazolin for prophylactic use during total hip arthroplasty. Animals - 10 dogs with hip dysplasia and 3 clinically normal dogs. Procedure - Blood samples and tissue specimens from the coxofemoral joint capsule, acetabulum, and femur were obtained during unilateral total hip arthroplasty. Cefazolin concentrations in serum and tissue specimen supernatant were determined, using high-performance liquid chromatography, for use in pharmacokinetic analysis. Mathematical simulation of serum cefazolin concentrations was used to to predict the optimal dose. Results - Mean pharmacokinetic constants (SEM) were 0.146 (0.013) min-1 for α. 4.74 min for t1/2α, 0.015 (0.004) min-1 for β, and 46.83 mm for t1/2β. Significant difference was not detected for cefazolin distribution and elimination between dogs with and without hip dysplasia. Additionally, significant difference was not observed in pharmacokinetic parameters describing distribution and elimination between the first and second doses of cefazolin The predicted optimal dosage regimen was 8 mg/ kg of body weight, IV, every hour or 22 mg/kg, IV, every 2 hours. Clinical Relevance - For prophylactic IV treatment during total hip arthroplasty, use of cefazolin at a dosage of 8 mg/kg every hour or 22 mg/kg every 2 hours should maintain serum cefazolin concentrations at least 10X the minimum inhibitory concentration for 3 to 4 hours.

UR - http://www.scopus.com/inward/record.url?scp=0030147275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030147275&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 720

EP - 723

JO - American Journal of Veterinary Research

JF - American Journal of Veterinary Research

SN - 0002-9645

IS - 5

ER -